Aclarion

Aclarion Enterprise Value

The Enterprise Value (EV) of Aclarion (ACON) as of Oct 20, 2026 is -8.58 M USD. In the previous year, Enterprise Value (EV) was 2.98 M USD — a change of -387.52% (lower).

Enterprise Value

-8.58 MUSD

YoY

-387.52%

Last updated:

Enterprise Value (EV) of Aclarion is 2025 -8.58 M USD. Enterprise Value (EV) of Aclarion was 2024 2.98 M USD. It decreases by -387.52% lower compared to the previous year.

The Aclarion Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
3.82 M USD
Jan 1, 2020
5.80 M USD
Jan 1, 2021
5.00 M USD
Jan 1, 2022
1.97 M USD
Jan 1, 2023
3.54 M USD
Jan 1, 2024
2.98 M USD
Jan 1, 2025
-8.58 M USD
The Aclarion Enterprise Value history
YEAREnterprise ValueYoY
-8.58 MUSD-387.52%
2.98 MUSD-15.76%
3.54 MUSD+79.88%
1.97 MUSD-60.66%
5.00 MUSD-13.70%
5.80 MUSD+51.62%
3.82 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aclarion Stock analysis

What does Aclarion do? Aclarion, Inc. generates revenue through its proprietary biomarker technology and signal processing software, which transforms raw Magnetic Resonance Spectroscopy (MRS) data into metabolic biomarkers for clinical use. The company's products are utilized by physicians to differentiate between painful and nonpainful lumbar spine discs, leveraging augmented intelligence in post-processing algorithms to quantify biomarker data and produce individualized ratio metrics against normative datasets. The firm targets healthcare providers focused on chronic low back pain treatment, offering solutions that optimize clinical decision-making through metabolic analysis. Aclarion's technology is centered on Magnetic Resonance Spectroscopy (MRS) and its proprietary biomarker, designed to assist physicians in determining disc-related pain in the lumbar spine. The company's signal processing software and expert system convert raw spectral MRS data into clear, actionable biomarkers, enabling tailored treatment approaches for chronic low back pain patients. By focusing exclusively on this clinical application, Aclarion serves a specialized segment of healthcare providers seeking advanced diagnostic tools for spinal conditions. Aclarion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aclarion stock

Enterprise Value (EV) of Aclarion is -8.58 M USD in 2025.

Enterprise Value (EV) of Aclarion changed from 2.98 M USD to -8.58 M USD, representing a -387.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Aclarion since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Aclarion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Aclarion

All Key Metrics — Aclarion